West Pharmaceutical Services WST Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about West Pharmaceutical Services's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is West Pharmaceutical Services's impairment charges?
- West Pharmaceutical Services (WST) reported impairment charges of $300K in Q1 2026.
- How has West Pharmaceutical Services's impairment charges changed year-over-year?
- West Pharmaceutical Services's impairment charges decreased by 0.0% year-over-year, from $300K to $300K.
- What is the long-term trend for West Pharmaceutical Services's impairment charges?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's impairment charges has grown at a 20.2% compound annual growth rate (CAGR), from $5.6M to $11.7M.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.